Scientific Resources
Search our resources — articles, case studies, presentations, and more — for answers to your biggest assay inquiries and drug discovery questions.
Blog Article
Three trends from SLAS2026 shaping assay development and HTS
In this blog article, we discuss three trends that emerged from SLAS2026 that will shape assay development and HTS strategies. Learn about implementing AI/ML (artificial intelligence and machine learning), the pursuit of novel, more complex, biological targets, and a drive towards multi-dimensional and parameter assay readouts.
All Peapod Bio Resources
Sort by Type
Search Resources
-
Assay development and high-throughput screen for Sortase A inhibitors using an innovative mass spectrometry platform to combat antibiotic resistant bacteria.
Abstract: Bacterial virulence is a driving mechanism of infection and disease. In Methicillin-sensitive and -resistant Staphylococcus aureus (MRSSA/MRSA), Sortase A plays a crucial role in bacterial virulence, where its transpeptidase activity anchors specific proteins like Staphylococcal protein A (SpA) to the cell wall enabling colonization and infection as well as facilitating resistance to antibiotics. Sortase
-
SLAS2026 Solutions Spotlight
Listen to Founder and CEO Zack Gurard-Levin creatively present Peapod Bio’s assay development and high-throughput screening capabilities along with its world-class screening collection and unique solutions that utilize surface chemistry to detect previously undetectable analytes using MALDI mass spectrometry.
-
Three trends from SLAS2026 shaping assay development and HTS
In this blog article, we discuss three trends that emerged from SLAS2026 that will shape assay development and HTS strategies. Learn about implementing AI/ML (artificial intelligence and machine learning), the pursuit of novel, more complex, biological targets, and a drive towards multi-dimensional and parameter assay readouts.
-
World class compound libraries and assays rapidly identify promising drug leads
Learn how Peapod Bio’s world-class collection of small molecules is launching drug discovery programs for even the most challenging targets.
-
Get your head out of your assay!
Introducing a new web series from Peapod Bio! In this series, CEO Zachary Gurard-Levin, PhD talks about the nuances of developing robust assays for small molecule drug discovery. He speaks with other assay experts about critical factors to consider that often extend beyond the assay well and protocol. Stay tuned every two weeks for new
-
Application of a MALDI mass spectrometry assay to identify covalent fragments targeting the methyl-lysine reader protein MPP8
In recent decades, the development of targeted covalent inhibitors (TCIs) has significantly advanced, as evidenced by the increasing number of FDA approved drugs with covalent mechanisms of action. This study focuses on the application of a robust and efficient screening platform to identify covalent fragments that modify the methyl-lysine reader protein M-phase phosphoprotein 8 (MPP8).
Explore Peapod Bio Solutions
Assay
Development
High-Throughput
Screening
Affinity Selection
Mass Spectrometry
Small Molecule Libraries
Ready to generate results?